B1 and B2 kinin receptor blockade improves psoriasis‐like disease
- 25 April 2020
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 177 (15), 3535-3551
- https://doi.org/10.1111/bph.15077
Abstract
Background and Purpose: Evidence indicates that the entire kallikrein‐kinin system is present in the skin, and it is thought to exert a relevant role in cutaneous diseases, including psoriasis. Thus, the present study was designed to evaluate the relevance of kinin receptors in the development and progression of a psoriasis mice model. Experimental Approach: Kinin B1 and B2 receptor knockout mice as well as C57BL/6 wild type (WT) mice treated with kinin receptor antagonists (SSR240612C or FR173657) were submitted to the Imiquimod (IMQ)‐induced psoriasis model. Key Results: Both kinin receptors were upregulated following 6 days of IMQ treatment. Kinin B1 and B2 receptor deficiency as well as the use of selective antagonists, show morphological and histological improvement of the psoriasis hallmarks. This protective effect was associated with a decrease in undifferentiated and proliferating keratinocytes, decreased cellularity (neutrophils, macrophages, CD4+ T lymphocytes), reduced γδ T cells as well as lower accumulation of IL‐17. The lack of B2 receptors resulted in reduced CD8+ T cells in the psoriatic skin. Relevantly, blocking kinin receptors reflected the improvement of psoriasis disease in the well‐being behaviour of the mice. Conclusions and Implications: The present results have provided clear experimental evidence that kinins exert a critical role in IMQ‐induced psoriasis. Both B1 and B2 kinin receptors exacerbate the disease development, influencing keratinocyte proliferation and immunopathology. Therefore, the use of antagonists for one or even both kinin receptors might constitute a new strategy for psoriasis clinical treatment.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (203667/2018‐2, 445822/2014‐7, 157002/2018‐7)
This publication has 67 references indexed in Scilit:
- The Role of Kinin Receptors in Preventing Neuroinflammation and Its Clinical Severity during Experimental Autoimmune Encephalomyelitis in MicePLOS ONE, 2011
- Proliferating cell nuclear antigen (PCNA): a key factor in DNA replication and cell cycle regulationAnnals of Botany, 2010
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Kinin B2receptor regulates chemokines CCL2 and CCL5 expression and modulates leukocyte recruitment and pathology in experimental autoimmune encephalomyelitis (EAE) in miceJournal of Neuroinflammation, 2008
- Association between the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene and risk for psoriasis in a Chinese population in TaiwanBritish Journal of Dermatology, 2007
- Fluvastatin Enhances Receptor-Stimulated Intracellular Ca2+Release in Human KeratinocytesBiochemical and Biophysical Research Communications, 1998
- Angiotensin-converting enzyme inhibitors as possible exacerbating drugs in psoriasisJournal of the American Academy of Dermatology, 1993
- Bradykinin Induces Phosphoinositide Turnover, 1,2-Diglyceride Formation, and Growth in Cultured Adult Human KeratinocytesJournal of Investigative Dermatology, 1990
- Bradykinin stimulates tumor necrosis factor and interleukin‐1 release from macrophagesFEBS Letters, 1989